Sugi Predict

Sugi Predict / Compounds / SCHEMBL6232939

SCHEMBL6232939

SCHEMBL6232939

Cc1sc(-c2ccccc2)cc1N

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.56
▸ KDM4E B2RXH2 5/20 0.56
▸ PKM P14618 3/20 0.56
▸ LMNA P02545 2/20 0.56
▸ RXFP1 Q9HBX9 1/20 0.56
▸ IKBKB O14920 4/20 0.53
▸ CYP1A2 P05177 1/20 0.53
▸ CYP3A4 P08684 1/20 0.53
▸ CYP2C9 P11712 1/20 0.53
▸ BTK Q06187 1/20 0.53
▸ ALDH1A1 P00352 6/20 0.51
▸ MEN1 O00255 4/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ HPGD P15428 4/20 0.51
▸ RAB9A P51151 4/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ NPC1 O15118 3/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ GAA P10253 4/20 0.46
▸ ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14817171 0.83 TUBB4A (0.44) MAPTKDM4EPKMLMNARXFP1
SCHEMBL5770536 0.80 MAPT (0.58) MAPTKDM4EPKMLMNARXFP1
SCHEMBL16272782 0.79 CYP3A4 (0.35) MAPTKDM4EPKMLMNARXFP1
SCHEMBL5491089 0.78 ALDH1A1 (0.58) MAPTKDM4EPKMLMNARXFP1
SCHEMBL114000 0.78 HSD17B1 (0.47) MAPTKDM4EPKMLMNARXFP1
SCHEMBL4260936 0.77 IKBKB (0.59) MAPTKDM4EPKMLMNARXFP1
SCHEMBL10205947 0.77 PLA2G10 (0.49) MAPTKDM4EPKMLMNARXFP1
SCHEMBL11888379 0.75 HSD17B1 (0.47) MAPTKDM4EPKMLMNARXFP1
SCHEMBL13739868 0.75 MAPT (0.40) MAPTKDM4EPKMLMNARXFP1
SCHEMBL6812091 0.75 MAPT (0.40) MAPTKDM4EPKMLMNARXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4651871-A2 ECTEINASCIDIN DERIVATIVE ANTIBODY DRUG CONJUGATES Adcytherix SAS (FR) 2025-11-26 — — EP disclosed
US-20250313555-A1 2-SUBSTITUTED THIAZOLE AND BENZOTHIAZOLE COMPOSITIONS AND METHODS AS DUX4 INHIBITORS ALTAY THERAPEUTICS, INC. 2025-10-09 — — US disclosed
EP-4622986-A1 BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS Elima Therapeutics, Inc. (US) 2025-10-01 — — EP disclosed
US-20250236594-A1 MODIFIED AMINO ACIDS SUTRO BIOPHARMA, INC. 2025-07-24 — — US disclosed
US-12269801-B2 Modified amino acids SUTRO BIOPHARMA, INC. (US) 2025-04-08 — — US disclosed
EP-2970357-B1 AMINO ACID PHOSPHORAMIDATE PRONUCLEOTIDES OF 2'-CYANO, AZIDO AND AMINO NUCLEOSIDES FOR THE TREATMENT OF HCV IDENIX PHARMACEUTICALS LLC (US) 2025-01-01 — — EP disclosed
US-20240254163-A1 HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY SUTRO BIOPHARMA, INC. 2024-08-01 — — US disclosed
WO-2024155565-A2 ECTEINASCIDIN DERIVATIVE ANTIBODY DRUG CONJUGATES YARROW THERAPEUTICS, INC. (US) 2024-07-25 — — WO disclosed
WO-2024145662-A1 2-SUBSTITUTED THIAZOLE AND BENZOTHIAZOLE COMPOSITIONS AND METHODS AS DUX4 INHIBITORS ALTAY THERAPEUTICS, INC. (US) 2024-07-04 — — WO disclosed
WO-2024112705-A1 BORONIC ACID AND BORONATE COMPOSITIONS AND METHODS ELIMA THERAPEUTICS, INC. (US) 2024-05-30 — — WO disclosed
EP-4174068-A1 NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING RESISTANT CANCER, COMPRISING SAME Holosmedic (KR) 2023-05-03 — — EP disclosed
US-11548852-B2 Modified amino acids SUTRO BIOPHARMA, INC. (US) 2023-01-10 — — US disclosed
EP-4074728-A1 MODIFIED PEPTIDES COMPRISING AN AZIDO GROUP Sutro Biopharma, Inc. (US) 2022-10-19 — — EP disclosed
EP-4032897-A1 MODIFIED FLUORINATED NUCLEOSIDE ANALOGUES Gilead Pharmasset LLC (US) 2022-07-27 — — EP disclosed
CN-114716506-A Hemiasterlin derivatives for conjugation and therapy 苏特罗生物制药公司 2022-07-08 — — CN disclosed
EP-3584255-B1 MODIFIED AMINO ACIDS COMPRISING AN AZIDO GROUP SUTRO BIOPHARMA INC (US) 2022-02-16 — — EP disclosed
WO-2020036243-A1 METHOD FOR SYNTHESIZING THIENO[3,2-B]PYRIDINE-5(4H)-ONE DERIVATIVE COMPOUND, USING GOLD CATALYST, AND USE THEREFOR 한국해양과학기술원 2020-02-20 — — WO disclosed
US-20080269481-A1 Compounds and methods for the treatment or prevention of Flavivirus infections VIROCHEM PHARMA INC. (CA) 2008-10-30 — — US disclosed
EP-1569929-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS Virochem Pharma Inc. (CA) 2005-09-07 — — EP disclosed
WO-2004052885-A1 COMPOUNDS AND METHODS FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS VIROCHEM PHARMA INC. (CA) 2004-06-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548852-B2 Modified amino acids PTMS, DNPEP, ANPEP MAPT 3167/4885KDM4E 2799/4885PKM 4111/4885
US-20250313555-A1 2-SUBSTITUTED THIAZOLE AND BENZOTHIAZOLE COMPOSITIONS AND METHODS AS DUX4 INHIBITORS DDX21, DDX42, CBX2 MAPT 1257/4885KDM4E 328/4885PKM 3421/4885
US-20240254163-A1 HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY CYP17A1, HSD17B7, SHBG MAPT 245/4885KDM4E 3122/4885PKM 3380/4885
US-12269801-B2 Modified amino acids PTMS, DNPEP, ANPEP MAPT 3167/4885KDM4E 2799/4885PKM 4111/4885
US-20250236594-A1 MODIFIED AMINO ACIDS PTMS, DNPEP, ANPEP MAPT 3167/4885KDM4E 2799/4885PKM 4111/4885
US-20080269481-A1 Compounds and methods for the treatment or prevention of Flavivirus infections ZC3HAV1, ZYX, ZFX MAPT 1641/4885KDM4E 1505/4885PKM 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.